249 results about "Viral Activity" patented technology

The present invention relates to the use of oligonucleotides having modified nucleobases to inhibit gene expression and / or replication of viruses in a subject. The modified nucleobases may be mercapto-modified bases or hydroxy-modified nucleobases. It is contemplated that the oligonucleotides further comprise a nuclease complex which enhances anti-viral activity of the oligonucleotides.

A method and system that reduces the length of time required to complete antivirus scans. An enhanced journal file system (JFS) includes an antivirus utility function, which utilizes a low level log of the JFS to store a history of transactions that occur since a previous scan operation. The log is immune from normal purge operations by the JFS and cannot be circumvented without driver level access. Thus, a virus that changes the timestamp on the file or otherwise attempts to hide its viral activity does not affect the log. When the antivirus scanning utility initiates an antivirus scan of the system, the antivirus scanning utility obtains the history since the last scan from the persistent log. The antivirus scanning utility “replays” the log and carries out the antivirus scan on all files, directories, etc. associated with any transactions that occurred since the last scan.

Imino sugars, such as deoxynojirimycin (DNJ), are glucose analogues that selectively inhibit cellular α-glucosidase I and II (enzymes that process N-linked glycans in glycoprotein) and exhibit broad spectrum antiviral activities against many enveloped viruses. Previously we have reported a novel DNJ derivative, OSL-95II, with antiviral activity and reduced cytotoxicity. In order to develop imino sugars with more potent antiviral activity as well as improved toxicity profile, OSL-95II was modified by diversifying the nitrogen linked alkylated side chain. The antiviral activities were initially tested in bovine viral diarrhea virus (BVDV) infected MDBK cells, yielding several imino sugar derivatives with novel structure and superior antiviral activity and toxicity profile. Furthermore, these new compounds were shown to be active against Dengue virus (DV) and West Nile virus (WNV) infection in BHK cells where potent anti-DV activity having submicromolar EC50 values and SI of greater than 900. These compounds represent a new generation of iminio sugars and their analogues, having application in the clinical treatment of infection of DV and other members of flaviviridae.

A method of treating, preventing or ameliorating one or more symptoms of hepatitis C, or inhibiting cathepsin activity, in a subject is provided, in which at least one compound (e.g., a HCV protease inhibitor) is administered in one or more discrete dosages over a twenty-four hour time interval in an asymmetric pattern as to dosage amount and / or timing of dosage, wherein the at least one compound is selected from the group consisting of compounds of Formulae I-XXVI, described herein. Methods of modulating the activity of hepatitis C virus protease in a subject are also provided. Asymmetric dosing as to amount of dose and / or timing of dose permits adjustment of dosing to accommodate variations in drug metabolism and / or viral activity caused by viral cell division or a patient's circadian rhythms, thus delivering the maximum amount of dose at the time or times it is most effective.

The present inventors have found that certain preparations containing LPS and / or lipid A variants, derivatives, and / or analogs demonstrate non-pyrogenic properties and exhibit anti-viral activities. In particular, non-pyrogenic preparations of LPS, lipid A, LPS antagonists and lipid A antagonists, and derivatives thereof induce beta chemokine secretion, such as MIP-1beta, but not proinflammatory cytokines, such as TNFalpha, IL-1beta and IL-6. Non-pyrogenic preparations of the invention have been demonstrated by the Applicant to suppress HIV replication in human peripheral blood monocytes, as described by way of example herein. The present invention provides preparations of LPS or lipid A variants, analogs and derivatives of decreased or absent pyrogenicity which can be used as therapeutics for the treatment or prevention of immunodeficiency virus infection and its consequences.

The present invention concerns methods and compositions for forming complexes of interferon-λ with an antibody or antigen-binding antibody fragment. In preferred embodiments, the interferon-λ and the antibody or fragment are fusion proteins, each comprising a dimerization and docking domain (DDD) moiety from human protein kinase A or an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP). In more preferred embodiments, the interferon-antibody complex is more efficacious for treatment of cancer, asthma, Alzheimer's disease, multiple sclerosis or viral infection than interferon-λ alone, antibody alone, or the combination of unconjugated interferon-λ and antibody.

A method of imparting a rapid and a persistent antiviral activity against viral-mediated diseases is disclosed. The method includes applying an antimicrobial compositions containing (a) a disinfecting alcohol, (b) an organic acid, and (c) water, and having a pH of about 5 or less, to at least one of the nose, nasal passages, and surrounding facial areas of skin of an individual.

Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral infections.

There are provided multimeric fusion proteins exhibiting anti-viral activity. The fusion proteins comprise the HR2 region of the ectodomain of the human immunodeficiency virus gp41 protein which is fused to a multimerisation domain peptide such as a trimerisation domain derived from tetranectin. The multimerised fusion proteins may be used as HIV fusion inhibitors in the treatment of AIDS.

The invention relates to a fatty acid composition, which is diluted at normal temperature and in cold water to form solution used for cleaning of sterilization, fungicide and antivirus. The fatty acid composition comprises at least the following components: component A: food fatty acid comprising at least octyl decanoic acid and nonanoic acid; component B: surfactant comprising alkane sulfonate; component C: acid. The fatty acid composition has the advantages that the fatty acid composition or the diluted solution thereof has good stability, bactericidal and antiviral activity under the water temperature of 4-20 DEG C, no phase separation or crystallization, thus having safer use performance, and active components are low in cost, having more broad-spectrum bactericidal activity which can kill various bacteria, epiphytes and viruses. The fatty acid composition or the diluted solution thereof can be used for sterilization, fungicide and antivirus, which has high-efficient and quick killing effect; the sterilizing rate can reach more than 99.999 percent with contact time less than 1 minute; The fatty acid composition or the diluted solution thereof also has strong cleaning ability, and can keep effective even in hard water; the killing ratio for poliovirus reaches 99.9999 percent and the poliovirus can be killed immediately.

The present invention provides: an antibacterial / antiviral composition which has excellent antibacterial / antiviral activity under visible light irradiation; an antibacterial / antiviral agent; a photocatalyst; and a bacteriairus inactivation method. An antibacterial / antiviral composition according to the present invention contains titanium oxide on which both a divalent copper compound and a silver compound are loaded. An antibacterial / antiviral agent according to the present invention and a photocatalyst according to the present invention contain an antibacterial / antiviral composition according to the present invention. A bacteriairus inactivation method according to the present invention inactivates bacteria and a virus with use of an antibacterial / antiviral composition according to the present invention, an antibacterial / antiviral agent according to the present invention or a photocatalyst according to the present invention.

A composition comprising of polyphenols, an ascorbic compound, lysine, and proline, have been found to retard viral activity. As such, methods of treating viral infection, and methods of retarding viral activity are provided herein.

Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and / or prophylactic / vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.

The present invention discloses an organic ionic compound having anti-viral activity and the method for antagonizing virus in vitro by putting the compounds in contact with the virus.

The invention discloses a photoconductive antivirus fabric and a manufacture method thereof. The photoconductive antivirus fabric prepared by the method comprises a photosensitive dye, a polyacrylic acid layer and a crosslinker and can absorb photons and act with surrounding oxygen to generate singlet oxygen under the illumination condition, the singlet oxygen can be oxidized to damage phospholipid and protein so as to damage a viral envelope and deactivate viral activity. For the protein, target amino acids to be damaged by the oxidized singlet oxygen comprise tryptophan, histidine, tyrosine, cysteine and methionine. The photoconductive antivirus fabric also acts on gram-positive bacteria and thus has the anti-virus and anti-bacterial action.

This disclosure relates to inventive methods for inactivating viral pathogens in which the steps of the methods include: (a) providing a virucidal composition comprising a liquid media containing less than 1% weight per volume cetylpyridinium chloride; and (b) contacting the virucidal composition with a surface targeted for disinfection. This disclosure further relates to inventive virucidal compositions, in which the compositions include: (a) a liquid media; (b) cetylpyridinium chloride in solution in the liquid media at a concentration of less than 1% weight per volume; (c) an extender; and (d) an enhancer.

The invention discloses an application of artemisinin and derivatives thereof in preparation of medicaments for treating hepatitis C viruses (HCV). The medicaments which almost do not have toxic concentration are used for anti-virus test; and by detecting the influence of the artemisinin and the derivatives thereof such as dicyanogen artemisinin, artemether and artesunate on HCV replication, the artemisinin and the derivatives thereof serving as small molecular compounds have remarkable viral activity resistance and are dose-dependent. The artemisinin and the derivatives thereof which have already been used for clinical antimalarials have low toxic or side effect on a human body. The artemisinin and the derivatives thereof which almost do not have toxicity can inhibit about 90 percent of HCV replication, and are efficient and low-toxic anti-HCV compounds. The compounds have a broad prospect for developing anti-HCV medicaments.

The invention provides alpha-pyrone compounds having antiviral activity and their application in resisting influenza viruses H1N1 and H3N2. The invention also discloses a preparation method of the alpha-pyrone compounds having antiviral activity, comprising: (1) acquiring a fermented material having rich pyrone compounds through microbial fermentation culture, wherein a recombinant vector used inthe microbial fermentation culture carries polyketide synthase having a nucleotide sequence of KU534995.1; (2) separating and purifying the fermented material of step (1) to obtain the alpha-pyrone compounds. Compared with existing drugs, the pyrone compounds have good anti-H2N1 and anti-H3N2 activity and are substantially nontoxic to normal cells; compared with existing drugs, the alpha-pyrone compounds have natural advantages, including good activity and toxic and side effects reduced as far as possible, and also have a promising application prospect and huge market.

The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.

The invention relates to human alpha-defensin 5 (HD5) antiviral active mutant polypeptide and preparation method and application. The 21th glutamic acid in HD5 of the amino acid sequence of the mutant polypeptide can be replaced into arginine (E21R). The preparation method of the mutant polypeptide has two preparation methods, namely a solid-phase chemical synthesis method and a gene engineering preparation method. The HD5 mutant polypeptide of the invention has efficient antiviral activity under the conditions that serum exits or absents, and compared with parent HD5 polypeptide, the antiviral function of the invention is obviously improved. The HD5 mutant polypeptide of the invention is used for preventing viral infection, such as HSV, HPV, HIV and the like.

The invention discloses an ophthalmic medicament and a preparation method thereof. The ophthalmic medicament comprises a phyllanthus emblica extract and water for injection. The ophthalmic medicamentcan provide a protective effect on viruses capable of being infected by eyes in a targeted manner; experimental research shows that the ophthalmic medicament has relatively efficient broad-spectrum antiviral activity, particularly has a remarkable treatment effect on new coronavirus and influenza virus, can effectively inhibit infection and propagation of the viruses, and has good prevention and control significance on propagation of diseases caused by virus infection on human bodies. The main effective components of the ophthalmic medicament are from natural plants, so that the ophthalmic medicament has the advantages of naturalness, safety, mild drug effect and the like, and the preparation method is simple, low in cost and very good in application prospect.

Peptides having activity of inhibiting infections of respiratory viruses and use of the same are disclosed. The peptides can be synthesized by chemical or genetic engineering methods, and they have functional domain capable of binding to surface glycoprotein of respiratory viruses and activity of inhibiting infections of respiratory viruses. The peptides are useful for blocking infections of respiratory viruses in target cells, for prevention / treatment of said infections, and for development of new prophylactic / therapeutic medicaments against respiratory viruses. Also disclosed are a kit for screening peptide capable of inhibiting said infections and the screening method. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic / therapeutic agents with broad-spectrum antiviral activities.

Viruses, and particularly RNA viruses, have high mutation rates. Hence, antiviral agents that have been developed to date targeting protease or reverse transcriptase of viruses have quickly lost their effectiveness and resistant viruses have emerged. Also, in recent years, viral diseases caused by various new viruses such as SARS, avian influenza, and the hepatitis C have become social menaces. Therefore, the development of a novel antiviral agent that can cope with a virus resistant to an existing drug or a new virus and has a wide range of applications has been demanded. The present invention provides a novel anti-RNA viral agent and a method for use thereof. The present invention further provides an anti-RNA viral agent that is also effective against a new virus or a drug-resistant virus, and a method for use thereof.